Table 2.
Demographic and clinical characteristics of ET-PD patients in comparison to ET-only, PD-only patients and controls
| Demographic and clinical characteristics |
Patients (n = 272) |
P value* | Controls (n = 101) | P value # | ||
|---|---|---|---|---|---|---|
| ET-PD (n = 15) | ET-only (n = 116) | PD-only (n = 141) | ||||
| Age, y |
69 ± 9.6 |
63.9 ± 14.4 |
64.4 ± 11.2 |
NS |
61.7 ± 12.4 |
NS |
| Gender (male) |
6 (40) |
39 (33.6) |
75 (53.2) |
0.007 |
56 (55.4) |
0.004 |
| Sympt. duration y |
6 (3-15) |
5 (1-10) |
3 (1-6) |
0.003a |
N/A |
N/A |
| Family history + |
8 (53.3) |
35 (31.3) |
23 (17) |
0.005 |
4 (4.3) |
<0.001 |
| Toxic exposure |
3 (20) |
19 (16.4) |
23 (16.3) |
NS |
16 (15.8) |
NS |
| Living in rural |
4 (26.7) |
19 (16.4) |
29 (20.6) |
NS |
16 (15.8) |
NS |
| Cogwheel sign |
4 (26.7) |
3 (2.6) |
129 (91.5) |
<0.001 |
0 (0) |
<0.001 |
| Pyramidal signs |
2 (13.3) |
3 (2.6) |
19 (13.5) |
0.009 |
10 (9.9) |
0.025 |
| H&Y stage |
2.6 ± 0.8 |
N/A |
1.8 ± 0.8 |
0.012 |
N/A |
N/A |
| UPDRS part I |
1 (0-1) |
1 (0-3) |
3 (1-4) |
NS |
N/A |
N/A |
| UPDRS part II |
5 (4-6) |
13 (12-13) |
11 (7-16) |
NS |
N/A |
N/A |
| UPDRS part III |
5 (3-6) |
4 (1-6) |
14 (9-20) |
0.021b |
N/A |
N/A |
| HAD-Anxiety |
1 (1-8) |
6 (2-10) |
8 (5-11) |
NS |
5 (3-8) |
NS |
| HAD-Depression |
4 (4-7) |
4 (2-6) |
6 (4-9) |
NS |
3 (1-7) |
NS |
| SF36-PF |
53.3 ± 17.6 |
52.3 ± 31.8 |
45.9 ± 25.3 |
NS |
70 ± 24.2 |
0.001c |
| SF36-RLPF |
16.7 ± 28.9 |
33.1 ± 29 |
33.3 ± 27 |
NS |
50.2 ± 29.4 |
0.020d |
| SF36-RLEF |
33.3 ± 57.7 |
51.4 ± 30 |
40.8 ± 34.2 |
NS |
59 ± 32.2 |
NSe |
| SF36-EF |
43.3 ± 10.4 |
43.8 ± 24.8 |
44.5 ± 19.4 |
NS |
58.8 ± 17.1 |
0.007f |
| SF36-EW |
66.7 ± 38.9 |
52.5 ± 26 |
53.7 ± 19.3 |
NS |
64.7 ± 15.8 |
NSg |
| SF36-SF |
58.3 ± 19.1 |
57.3 ± 31.5 |
53.8 ± 24.9 |
NS |
75.7 ± 46.7 |
0.050h |
| SF36-P |
66.7 ± 18.8 |
65.7 ± 26.7 |
49.5 ± 30.7 |
NS |
61.7 ± 28.2 |
NS |
| SF36-GH | 28.3 ± 2.9 | 35 ± 19.4 | 31.1 ± 16.9 | NS | 49.1 ± 18.5 | <0.001i |
Values are presented as mean ± SD or median with IQR, and numbers (percentages). *- p values were counted comparing 3 groups of patients, #- p values were counted comparing 4 groups of subjects where available.
The post hoc multiple comparisons between the groups by Tukey HSD and LSD tests revealed significant differences:
a-ET-PD vs. PD-only p = 0.001, 95% CI 2.8-13.1, ET-only vs. PD-only p = 0.002, 95% CI 1.12-5.87; b-LSD test only PD vs. ET-only p = 0.009, 95% CI 2.32-15.61; ET-PD vs. ET-only p = 0.008, 95% CI 4.86-31.08; c-PD-only vs. control group p = 0.001, 95% CI 8.37-39.88; d-PD-only vs. control group p = 0.05, 95% CI 0.01-33.83; e-LSD test only, PD-only vs. control group p = 0.018, 95% CI 3.16-33.19; f-PD-only vs. control group p = 0.011, 95% CI 2.48-26.16; ET-only vs. control group p = 0.024, 95% CI 1.46-28.67; g-LSD test only, PD-only vs. controls p = 0.021, 95% CI 1.66-20.19; ET-only vs. controls p = 0.026, 95% CI 1.46-22.76; h-PD-only vs. control group p = 0.039, 95% CI 0.77-43.1; i-PD-only vs. controls p < 0.001, 95% CI 7.24-28.62; ET-only vs. controls p = 0.018, 95% CI 1.77-26.34; LSD test only, PD-only vs. ET-only p = 0.031, 95% CI 1.52-30.94.